By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) To Merge Research And Development And Implement Changes Within The Management Group 9/16/2015 12:02:23 PM
Medivir (MVRBF) – Interim Report, Second Quarter 2015 8/20/2015 8:55:11 AM
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir On AL-335 Pharmacokinetics 8/3/2015 11:32:57 AM
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015 10:28:04 AM
Medivir (MVRBF) Announces That Janssen Submitted Supplemental New Drug Application To U.S. FDA For OLYSIO (Simeprevir) In Combination With Sofosbuvir 7/24/2015 11:07:54 AM
Medivir (MVRBF): OLYSIO Sales During The Second Quarter 2015 7/14/2015 11:58:16 AM
Medivir (MVRBF) Announces The First Cancer Project Derived From Its In-House Nucleotide Platform 6/30/2015 12:07:52 PM
Medivir (MVRBF) Reorganizes and Ditches Neuropathic Pain R&D 6/16/2015 5:57:24 AM
Medivir AB (MVRBF)’s Board Of Directors Has Resolved To Repurchase Own Shares 5/6/2015 9:58:59 AM
Medivir AB (MVRBF): Positive Preclinical Antiviral And Safety Profile Of MIV-802 Supports Continued Development 4/23/2015 8:36:05 AM